Biomarker testing can help to guide treatment planning

Cancer is a disease of our genes 

Cancer is caused when abnormalities in DNA (for example, mutations) lead to changes in a gene’s function, to promote uncontrollable cell growth, tumor survival, and metastasis. While some genetic mutations are inherited, which may lead to an increased risk of cancer formation, other mutations, called genomic mutations, are formed and present only within cancer (tumor) cells.

Learn more about genes and cancer with the American Cancer Society.

Reference: 1. American Cancer Society. Genetics and Cancer. Accessed January 2024.

Precision medicine in cancer means working towards a targeted treatment plan based on comprehensive biomarker profiling 

A tumor’s comprehensive biomarker profile can be used to make a diagnosis, to determine treatment options based on gene mutations, and to evaluate the effectiveness of treatment– this is called precision medicine. Some therapies targeting specific genomic changes are approved and available for use in clinical practice, while many are currently under investigation in clinical studies. Biomarker testing can provide a molecular profile of your tumor, which may give information on whether an approved therapy or clinical study could be an option.

Learn more about precision medicine with the American Cancer Society.

Reference: 1. American Cancer Society. Biomarker Tests and Cancer Treatment. Accessed January 2024. 

Next-generation sequencing (NGS) testing can identify gene mutations

NGS is a method of biomarker testing which identifies any genomic mutations. NGS can provide important information to determine available treatments or clinical study options. The TP53 Y220C mutation results in a mutated p53 Y220C protein which is a key treatment target in cancer that has been identified in >30 different solid tumor types.1,2 NGS can identify the TP53 Y220C mutation.

To learn more about NGS testing, please visit JAMA Oncology.

References: 1. Ewalt MD, et al. JAMA Oncol. 2019;5(7):1076; 2. Dumbrava EE, et al. Oral presentation at ASCO 2022, Chicago, USA. June 3–7, 2022; 3. Bauer M, et al. Future Med Chem. 2019;11(19):2491–2504.

Further information on clinical studies

Learn more about clinical studies with the National Cancer InstituteAmerican Cancer Society, and European Medicines Agency.

If you are interested in taking part in a clinical trial, the Leal Health service can help find the right trial for you, for free. Click here for more information.

​To learn more about rezatapopt (also known as PC14586) in the PYNNACLE study, please visit

Please contact the PMV Pharmaceuticals Clinical Study Information Center

+1 (609) 235-4038

Medical Information Request Form

For healthcare providers as well as patients and their caregivers to query PMV Pharmaceuticals for additional Medical Information.

Click here or scan the QR code for the Medical Information Request Form

Rezatapopt is an investigational agent that has not been approved by the US FDA, EMA or any other regulatory agency for the treatment of cancer.

MA-586-0014 February 2024